{"analyses":[{"ciLowerLimit":"31.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"49.10","estimateComment":"95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Difference in MRD Negative Rates","paramValue":"40.28","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.83","upperLimit":"41.95","value":"35.2"},{"groupId":"OG001","lowerLimit":"69.17","upperLimit":"81.05","value":"75.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"MRD negativity was defined as having \\< 1 CLL cell per 10,000 leucocytes in peripheral blood.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood as Measured by Allele-Specific Oligonucleotide Polymerase Chain Reaction (ASO-PCR) at Completion of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}